CanSino Biologics (HKG:6185, SHA:688185) obtained approval to conduct a phase I clinical trial of its inhaled tuberculosis vaccine from Indonesia's drug regulator, a Thursday Hong Kong bourse filing said.
The study will investigate the safety and immunogenicity of a single dose of the vaccine in adults aged 18 to 49 years, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.